Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209051 · ClinicalTrials.gov registry record · NA
Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers
A NA study, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT02209051 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 29 participants.
The verdict
NCT02209051, a NA study, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
The primary goal of the study is to demonstrate the increased rate of complete wound closure by AMNIOEXCEL® compared to routine care in patients with chronic diabetic foot ulcers
Interventions
- OTHER AMNIOEXCEL
- OTHER Standard of Care, Diabetic Foot Ulcers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209051
The ClinicalTrials.gov registry entry for NCT02209051 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMNIOEXCEL is the first listed.
NCT02209051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02209051 about?
NCT02209051 is a clinical study titled "Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers". The primary goal of the study is to demonstrate the increased rate of complete wound closure by AMNIOEXCEL® compared to routine care in patients with chronic diabetic foot ulcers
What is the current status of trial NCT02209051?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2014-07. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02209051?
The interventions under investigation include: AMNIOEXCEL (OTHER), Standard of Care, Diabetic Foot Ulcers (OTHER).
Who is sponsoring clinical trial NCT02209051?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.